MVP Act
U.S. Congress · HR7871 ·
Progression
Timing in context
Primary sponsor's contributions received (same period)
Adjacency in time is shown for context; it is not evidence of cause. Funded ≠ false — see the methodology.
What the bill says
Introduced 2026-03-09. Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Summary (plain-language)
Medicaid VBPs for Patients Act or the MVP Act This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. ( Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.) The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes. Additionally, the bill (1) exempts sales of drugs that are made under value-based purchasing arrangements from calculations of the manufacturer average sales price for purposes of payments under Medicare medical services, if the manufacturer reports multiple best prices under Medicaid in accordance with the bill's changes; and (2) requires the Centers for Medicare & Medicaid Services to issue guidance on how state Medicaid programs may cover drugs in inpatient settings via value-based purchasing arrangements.
Sponsors
- Brett Guthrie (primary)
- Jake Auchincloss
- Gus M. Bilirakis
- Troy Balderson
- Kat Cammack
- Earl L. "Buddy" Carter
- Donald G. Davis
- Neal P. Dunn
- Glenn Ivey
- John Joyce
- Mike Kelly
- Ted Lieu
- Daniel Meuser
- Mariannette Miller-Meeks
- Kevin Mullin
- Scott H. Peters
- Beth Van Duyne
- Joe Wilson
Text versions
- Introduced in House — 2026-03-09 — XML
What analysts say
No nonpartisan analysis on file for this measure yet.
What politicians say
No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.
Action History
| Date | Action |
|---|---|
| 2026-03-09 | Introduced in House |
| 2026-03-09 | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |